Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanomaRecent Posts
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023